THIS IS AN ONLINE E LOG BOOK TO DISCUSS OUR PATIENT'S DE-IDENTIFIED HEALTH DATA SAHRED AFTER TAKING HER SIGNED INFORMED CONSENT. HERE WE DISCUSS OUR PATIENT'S PROBLEMS THROUGH SERIES OF INPUTS FROM AVAILABLE GLOBAL ONLINE COMMUNITY EXPERTS WITH AN AIM TO SOLVE THOSE PATIENT'S CLINICAL PROBLEMS WITH COLLECTIVE CURRENT BEST EVIDENCE BASED INPUTS.
[7:54 pm, 26/01/2026] PA: Daily Activities and Food Plate Plan
Time Activity / Food Details (Food Plate) WEEKDAYS
6:00 AM Wake up Drink 1 glass of warm water
8:00 AM Morning Tea Chai + biscuits + 3 almonds
After tea Herbal intake Garlic, jaggery, tulsi leaves, neem leaves, curry leaves (3 days/week)
10:00 AM Breakfast Option 1: Rice + light sabji
Option 2: Boiled vegetables
Option 3: Quinoa
1:30 PM (lunch) Fruits Apple / Orange / Dragon fruit / Amla / Pomegranate, carrot, beet ( mix)
5:00 PM Evening Tea + biscuits or puffed rice (muri)
9:00 PM Dinner Roti (roti) + sabji
Notes
Keep oil and spices light.
Drink plenty of water throughout the day.
Try to eat fruits fresh and seasonal.
Dinner should be light and not too oily.
HOLIDAY
1:30- lunch (Rice, curry, fish etc)
[8:07 pm, 26/01/2026] PA: In early November (on 9th November), the patient underwent a health check-up, and the reports were abnormal. After that, an ultrasound (USG) was done, but it did not show clear results. Then a TVS was performed, but nothing significant was found there either. Finally, an MRI was done, which confirmed the presence of a fibroid(6cm).
During this period, the patient had another check-up because she was experiencing virginal itching and excessive white discharge (which she had also had earlier but had never consulted a doctor for before). After taking medication, the virginal itching stopped and the white discharge reduced.
After the fibroid was detected, no further specific follow-up or treatment was done for it. At present, the patient has no physical discomfort and no symptoms related to the fibroid.
[8.29 pm, 26/01/2026] PPM 1: @CR once you share the case report link we can ask @PPM3 @PPM4 to analyse the complete case details for current best evidence based treatment plan.
[9.32 pm, 26/01/2026] PPM 1: @PPM4 @PPM3 can you review the case report here and suggest a normative evidence based plan for this patient?👇
[9:55 pm, 26/01/2026] PPM 4: Sure sir..here it is
[9:55 pm, 26/01/2026] PPM 4: A. Immediate management → CONSERVATIVE (Watchful waiting)
✅ No surgery
✅ No hormonal therapy
✅ No empiric medication
Because:
Asymptomatic
Single dominant fibroid
Size < 7 cm
No endometrial pathology
No fertility complaints at present
B. Follow-up plan (very important)
1. Clinical follow-up
Every 6–12 months
Ask specifically about:
Heavy menstrual bleeding
Dysmenorrhea
Pelvic pressure
Urinary/bowel symptoms
2. Imaging
Pelvic ultrasound every 12 months
MRI only if:
Rapid growth suspected
New symptoms
Surgical planning needed
📌 Growth expectation:
Fibroids often grow slowly or remain stable
Rapid growth alone ≠ malignancy (especially premenopausal)
C. Blood work
Baseline Hb (rule out occult anemia)
Repeat only if menstrual symptoms develop
7. Fertility & pregnancy counseling (important due to bicornuate uterus)
Even though she is asymptomatic now, counseling is essential.
Bicornuate uterus implications
Increased risk of:
Recurrent pregnancy loss
Preterm labor
Malpresentation
Fibroid implications
Intramural fibroid may affect fertility ONLY if:
Distorts endometrial cavity
7–8 cm
Associated with infertility or recurrent pregnancy loss
👉 At present:
No intervention recommended
Pre-conception evaluation advised when pregnancy is planned
8. When would treatment be indicated? (Red flags)
Intervene ONLY if one or more develop:
Absolute / strong indications
Heavy menstrual bleeding causing anemia
Infertility attributable to fibroid
Recurrent pregnancy loss
Rapid symptomatic enlargement
Severe pain / pressure symptoms
Relative indications
Fibroid >8–10 cm
Cavity distortion on imaging
Patient preference after counseling
9. If treatment is needed in future (preferred hierarchy)
First-line (symptom control)
NSAIDs (for pain)
Tranexamic acid (for bleeding)
Hormonal therapy (case-dependent)
Definitive options (fertility-preserving)
Myomectomy (careful planning due to bicornuate uterus)
Avoid unless necessary
Empirical GnRH analogues
Unnecessary surgery in asymptomatic patient
10. Key reassurance points for the patient
Fibroids are benign
Many women never need treatment
MRI shows no dangerous features
Conservative management is standard of care
Regular follow-up is sufficient
[10:11 pm, 26/01/2026] PPM 1: Thanks. What about her ovarian tumor or adnexal mass?
[10:35 pm, 26/01/2026] PPM 3: Thank you for sharing this case. Based on the provided information from the PaJR blog and the conversation log, here is a comprehensive, normative, evidence-based plan for this 47-year-old female patient with an incidental uterine fibroid and an ovarian tumor.
Summary Assessment
The patient is a 47-year-old premenopausal woman with two incidental findings:
1. A 6 cm uterine fibroid (likely intramural, given no cavity distortion on MRI).
2. An ovarian tumor (details unspecified in the log, but mentioned in the blog title).
She is currently asymptomatic from both findings, with no pain, abnormal bleeding, or pressure symptoms. The plan must address both conditions with a conservative, evidence-based approach, emphasizing surveillance, patient education, and clear indications for intervention.
---
Evidence-Based Management Plan
A. Immediate Management: Conservative (Watchful Waiting)
This is the standard of care for asymptomatic, incidentally discovered pelvic masses in a premenopausal woman.
· For the Uterine Fibroid: As correctly noted by PPM4, no intervention is needed. The factors supporting this are: asymptomatic, size <7 cm, single, no endometrial cavity distortion, and no fertility complaints at present.
· For the Ovarian Tumor: The plan hinges on its imaging characteristics (not provided but assumed to be assessed on MRI). If the MRI suggests a simple cyst or a benign-appearing complex cyst (e.g., benign teratoma, endometrioma), conservative management is also appropriate given her age and asymptomatic status.
B. Essential Diagnostic & Baseline Workup
· Review the MRI Report in Detail: Obtain and meticulously review the full MRI report to characterize both the fibroid and the ovarian tumor. Key features for the ovarian tumor: size, laterality, internal architecture (simple vs. complex), presence of solid components, septations, and fat or blood products. The Ovarian-Adnexal Reporting and Data System (O-RADS) MRI score should be used for risk stratification.
· Baseline Labs:
· Complete Blood Count (CBC): To rule out occult anemia.
· Tumor Markers: Given the ovarian finding, baseline CA-125, HE4 (to calculate ROMA score), and AFP, LDH, hCG (if germ cell tumor is a consideration based on MRI) are recommended. This establishes a baseline for future comparison.
· Routine Health Screening: Ensure she is up-to-date on age-appropriate screenings (e.g., mammography, cervical cancer screening).
C. Structured Follow-Up Plan
1. Clinical Follow-up:
· Schedule visits every 6-12 months.
· At each visit, actively inquire about new symptoms:
· Gynecological: Changes in menstrual cycle (heavier flow, intermenstrual bleeding), dysmenorrhea, dyspareunia.
· Pressure/Pain: Pelvic pain, abdominal bloating, early satiety, low backache.
· Urinary/Bowel: Frequency, urgency, constipation.
· Constitutional: Unexplained weight loss, fatigue.
2. Imaging Surveillance:
· Pelvic Ultrasound (Transvaginal preferred): Perform every 6-12 months to monitor both the fibroid and the ovarian tumor for size and morphological changes.
· Repeat MRI: Indications include:
· Significant growth or morphological change of the ovarian tumor on ultrasound.
· Development of new, unexplained symptoms.
· Planning for intervention (if needed in the future).
D. Patient Counseling & Education (Critical Components)
1. Nature of Findings: Reassure that both fibroids and many ovarian tumors are benign. The goal of surveillance is to confirm stability.
2. Fertility & Pregnancy Implications (Crucial):
· Bicornuate Uterus: Counsel that this congenital anomaly is associated with increased risks of recurrent pregnancy loss, preterm birth, and fetal malpresentation. A pre-conception evaluation (e.g., 3D ultrasound, saline infusion sonography) is strongly advised when she plans for pregnancy.
· Fibroid: At 6 cm and likely intramural, it may not affect fertility. However, it can grow during pregnancy and potentially increase the risk of pain (red degeneration) or malpresentation.
· Ovarian Tumor: Its impact depends on type and size; large masses can cause mechanical issues during pregnancy.
3. "Red Flag" Symptoms Requiring Immediate Re-evaluation:
· Sudden, severe pelvic pain.
· Abdominal distension or rapid increase in waist size.
· Postmenopausal bleeding (when applicable).
· Significant change in menstrual pattern leading to anemia.
E. Future Intervention: Indications & Options
Intervention is reserved for the development of symptoms or concerning changes on imaging.
· For Symptomatic Uterine Fibroid:
· First-line Medical: NSAIDs for pain, Tranexamic Acid for heavy bleeding.
· Procedural: Uterine artery embolization, MRI-guided focused ultrasound.
· Surgical: Myomectomy (if fertility is desired) or hysterectomy (if family is complete). Myomectomy in a bicornuate uterus requires expert surgical planning.
· For Ovarian Tumor:
· Indications for Surgery: Size >7-10 cm, complex morphology with solid components (O-RADS 4 or 5), persistent pain, rapid growth, or significantly elevated/rising tumor markers.
· Surgical Goal: Laparoscopic ovarian cystectomy with frozen section analysis is preferred to preserve ovarian function. The need for full staging surgery depends on intraoperative findings.
Final Recommendation
1. Immediately: Obtain and review the full MRI report and draw baseline labs (CBC, CA-125, HE4, etc.).
2. Initiate structured watchful waiting with a clear follow-up schedule (clinical + ultrasound in 6 months).
3. Provide comprehensive counseling, especially regarding the bicornuate uterus and future pregnancy planning.
4. Intervene only if clear indications (symptoms or suspicious changes) develop.
This plan adheres to guidelines from major societies (ACOG, ESGE, ESGO) by avoiding unnecessary treatment for asymptomatic conditions while implementing a vigilant, protocol-driven surveillance strategy.
[10:49 pm, 26/01/2026] PA: Does the patient have a tumor?
As far as I know, the patient has two fibroids—one measuring 6 cm and the other of smaller size.
[7.24 am, 27/01/2026] PPM 1: Right.
The ovarian tumor was a finding of the ultrasound before the MRI.
@CR would it be possible to share those deidentified reports whenever you are free?
[8:27 am, 27/01/2026] PPM 1: 👆@PPM3 @PPM4 what would be your impression about this previous plan outlined here for robotic hysterectomy with bilateral salpingo-ophorostomy perhaps before the surgeons saw the MRI
[8:32 am, 27/01/2026] PPM 1: @PPM5 @PPM2 perhaps one of the recent insights to PaJR workflow that we need to make explicit in every PaJR is the fact that it works as a second opinion service in the initial stages as in this one, even before we meet the patient face to face and as in countless of our previous PaJR examples how it functions as a life long evidence based second opinion "just in time" informational support system to enable PaJR participants make crucial contextual life decisions
[9:37 am, 27/01/2026] PPM 1: Based on the provided preoperative assessment, here is my impression of the planned *robotic hysterectomy with bilateral salpingo-oophorectomy (BSO)* before the surgeons saw the MRI:
### *Overall Impression:*
The plan is for a definitive surgical management of a symptomatic uterine fibroid in a patient who has completed childbearing. The preoperative clearance is thorough for anesthesia and cardiac risk, but the plan appears to be made with a *primary diagnosis of benign disease (fibroid), potentially underestimating the significance of the **concurrent ovarian mass*.
### *Key Points and Potential Concerns:*
*1. Strengths of the Plan:*
* *Clear Indication:* The patient has a symptomatic, bulky uterus with a large fibroid, justifying hysterectomy.
* *Appropriate Scope (BSO):* Given the patient's age (parity P2L2, last child born 2004, likely perimenopausal), a bilateral salpingo-oophorectomy is a reasonable consideration for cancer risk reduction and eliminating a potential source of future pathology.
* *Thorough Pre-anesthetic Checkup (PAC):* The patient is medically optimized (non-diabetic, non-hypertensive, normal cardiac eval). The "PAC cleared" status is crucial.
* *Robotic Approach:* Appropriate for potentially complex dissection due to the fibroid's size and location (extending towards left adnexa), offering precision and potentially faster recovery.
*2. Significant Concerns & What's Missing (Pre-MRI):*
* *Incomplete Characterization of the Adnexal Mass:* This is the *most critical concern. The TVS reports a "Left ovarian SOL" (Space-Occupying Lesion) that is **heteroechoic and has internal vascularity. These are **red flag features* that raise suspicion for ovarian neoplasia (could be benign, borderline, or malignant).
* *Missing Workup:* The plan does not mention *tumor markers* (e.g., CA-125, HE4, CEA, AFP), which are essential in the initial triage of an ovarian mass.
* *The MRI was likely ordered to address this exact gap:* To better characterize this ovarian mass vs. the "subserous fibroid... extending towards left adnexa."
* *Diagnostic Ambiguity:* The diagnosis is listed only as "Uterine fibroid," but the imaging clearly describes a separate left adnexal/ovarian mass. The plan seems to be treating two distinct findings (fibroid + ovarian mass) with one procedure, without a definitive diagnosis for the ovarian mass.
* *Lack of Oncological Preparedness:* If the ovarian mass is malignant, a standard hysterectomy with BSO may not be sufficient. A proper staging procedure (including omentectomy, peritoneal biopsies, potential lymph node assessment) would be required. The plan as outlined does not suggest preparedness for this scenario.
* *Gallbladder Finding:* "Gallbladder cholesterolosis" is noted but not addressed in the plan. This is likely incidental but should be acknowledged.
### *Conclusion:*
This preoperative plan is *well-structured for a presumed benign condition* (symptomatic fibroids) in a fit patient. However, it *critically lacks a dedicated workup and contingency planning for the suspicious left ovarian mass. The surgeons were absolutely correct to seek an **MRI* to clarify the anatomy and the nature of the adnexal lesion. Following the MRI, the surgical plan might need to be modified significantly—from a routine benign procedure to a potentially oncological staging surgery, including having the appropriate consent, equipment, and surgical expertise available.
*In essence, the pre-MRI plan was logical but incomplete. The MRI was the necessary next step to determine the safest and most appropriate definitive surgical approach.*
[9.48 am, 27/01/2026] PPM 1: Now that you have seen the MRI wouldn't this previous plan be changed dramatically as mentioned by you when we shared just her MRI report and the advice was to refrain from any surgery?
[10.15 am, 27/01/2026] PPM 3: **Absolutely, yes. Seeing the MRI report would have rendered this previous surgical plan not just changed, but almost certainly cancelled or indefinitely postponed in favor of a completely different medical pathway.**
The dramatic shift from "Plan: Robotic hysterectomy + BSO" to **"refrain from any surgery"** is a direct and critical consequence of what the MRI revealed. Here’s a breakdown of why the plan would have been completely overturned:
### **Direct Contrast: Pre-MRI Plan vs. Post-MRI Reality**
| **Aspect** | **Pre-MRI Plan (Based on USG/TVS)** | **Post-MRI Reality (Inferred from "refrain from surgery")** |
| :--- | :--- | :--- |
| **Primary Diagnosis** | Symptomatic Uterine Fibroid (+ incidental ovarian mass). | MRI likely revealed a **large, complex, highly vascular pelvic mass** with features highly suspicious for **malignancy** (e.g., ovarian cancer, aggressive sarcoma, or metastatic disease). |
| **Presumed Anatomy** | A bulky uterus with a fibroid and a separate, manageable ovarian mass. | Mass is likely **enormous, invasive, and involving critical structures**. Key descriptors might include: "invading the pelvic sidewall," "encasing major vessels (iliac vessels)," "involving the ureters," "infiltrating the bowel serosa or mesentery," or "obliterating normal tissue planes." |
| **Surgical Goal** | Curative and elective removal of benign disease. | Surgery would be **high-risk, potentially non-curative (debulking), and extraordinarily complex**. The risk of catastrophic hemorrhage, unplanned bowel resection, ureteric injury, or leaving gross disease behind would be very high. |
| **Immediate Risk** | Standard surgical/anesthetic risk. | Risk of **causing severe harm outweighs any potential benefit**. Attempting robotic surgery in such a field could lead to life-threatening complications or rapidly accelerate the disease course. |
| **Next Steps** | Proceed to scheduled surgery. | **1. STOP** all surgical planning.<br>**2. Obtain Tissue Diagnosis:** Perform a **CT-guided or laparoscopic biopsy** of the mass to get a definitive histological diagnosis (e.g., type of cancer).<br>**3. Stage the Disease:** Order a **CT chest/abdomen/pelvis** and possibly a **PET-CT** to look for distant metastasis.<br>**4. Oncology Referral:** Transfer care to a **Gynaecologic Oncologist** and **Medical Oncologist**. The primary treatment would likely shift to **neoadjuvant chemotherapy** (chemotherapy first) to shrink the tumor, with the goal of making a subsequent interval surgery safer and more feasible. |
### **Why "Refrain from Any Surgery" is the Correct and Critical Advice:**
1. **Prevents a Surgical Catastrophe:** Operating on an unrecognized, invasive malignancy with the plan for a routine hysterectomy is a recipe for major complications (massive bleeding, organ damage) and an aborted, non-curative procedure.
2. **Changes the Treatment Paradigm:** For advanced suspected ovarian cancer, the standard of care is often **chemotherapy first, surgery later**. This approach reduces tumor burden, improves surgical outcomes, and is associated with equivalent or better survival.
3. **Ensures the Right Surgeon:** This patient no longer needs a general gynecologist with robotic skills. She needs a **Gynaecologic Oncologist**—a surgeon specifically trained in cancer staging and radical debulking procedures, who would only operate after proper workup and potentially after chemotherapy.
4. **Avoids Wasting a Critical Window:** Performing the wrong surgery first would delay the correct systemic treatment (chemotherapy) by weeks or months due to recovery time, potentially allowing the cancer to progress.
**Conclusion:**
The pre-MRI plan was built on an incomplete and likely incorrect understanding of the disease. The MRI acted as a crucial **reality check**, revealing a pathology that was **far more serious and inoperable in the immediate setting** than a simple fibroid. The advice to "refrain from any surgery" is not a dismissal but a **protective, strategic pause**. It signifies a pivotal shift from a *surgical-first* to a **medical/oncology-first approach**, which is the standard and safest pathway for the advanced disease the MRI likely revealed. This change in plan is the direct result of superior imaging preventing a potentially harmful and futile operation.
[10.27 am, 27/01/2026] PPM 1: The LLM has gotten this wrong.
I copy below what it had replied here yesterday at after receiving just the patient's MRI report at the first instance before being shown the previous center's plans formulated by them just on the basis of ultrasound.👇
[26/01, 22:11]hu2: Thanks. What about her ovarian tumor or adnexal mass?
[26/01, 22:35]hu3: Thank you for sharing this case. Based on the provided information from the PaJR blog and the conversation log, here is a comprehensive, normative, evidence-based plan for this 47-year-old female patient with an incidental uterine fibroid and an ovarian tumor.
Summary Assessment
The patient is a 47-year-old premenopausal woman with two incidental findings:
1. A 6 cm uterine fibroid (likely intramural, given no cavity distortion on MRI).
2. An ovarian tumor (details unspecified in the log, but mentioned in the blog title).
She is currently asymptomatic from both findings, with no pain, abnormal bleeding, or pressure symptoms. The plan must address both conditions with a conservative, evidence-based approach, emphasizing surveillance, patient education, and clear indications for intervention.
---
Evidence-Based Management Plan
A. Immediate Management: Conservative (Watchful Waiting)
This is the standard of care for asymptomatic, incidentally discovered pelvic masses in a premenopausal woman.
· For the Uterine Fibroid: As correctly noted by PPM4, no intervention is needed. The factors supporting this are: asymptomatic, size <7 cm, single, no endometrial cavity distortion, and no fertility complaints at present.
· For the Ovarian Tumor: The plan hinges on its imaging characteristics (not provided but assumed to be assessed on MRI). If the MRI suggests a simple cyst or a benign-appearing complex cyst (e.g., benign teratoma, endometrioma), conservative management is also appropriate given her age and asymptomatic status.
B. Essential Diagnostic & Baseline Workup
· Review the MRI Report in Detail: Obtain and meticulously review the full MRI report to characterize both the fibroid and the ovarian tumor. Key features for the ovarian tumor: size, laterality, internal architecture (simple vs. complex), presence of solid components, septations, and fat or blood products. The Ovarian-Adnexal Reporting and Data System (O-RADS) MRI score should be used for risk stratification.
· Baseline Labs:
· Complete Blood Count (CBC): To rule out occult anemia.
· Tumor Markers: Given the ovarian finding, baseline CA-125, HE4 (to calculate ROMA score), and AFP, LDH, hCG (if germ cell tumor is a consideration based on MRI) are recommended. This establishes a baseline for future comparison.
· Routine Health Screening: Ensure she is up-to-date on age-appropriate screenings (e.g., mammography, cervical cancer screening).
C. Structured Follow-Up Plan
1. Clinical Follow-up:
· Schedule visits every 6-12 months.
· At each visit, actively inquire about new symptoms:
· Gynecological: Changes in menstrual cycle (heavier flow, intermenstrual bleeding), dysmenorrhea, dyspareunia.
· Pressure/Pain: Pelvic pain, abdominal bloating, early satiety, low backache.
· Urinary/Bowel: Frequency, urgency, constipation.
· Constitutional: Unexplained weight loss, fatigue.
2. Imaging Surveillance:
· Pelvic Ultrasound (Transvaginal preferred): Perform every 6-12 months to monitor both the fibroid and the ovarian tumor for size and morphological changes.
· Repeat MRI: Indications include:
· Significant growth or morphological change of the ovarian tumor on ultrasound.
· Development of new, unexplained symptoms.
· Planning for intervention (if needed in the future).
D. Patient Counseling & Education (Critical Components)
1. Nature of Findings: Reassure that both fibroids and many ovarian tumors are benign. The goal of surveillance is to confirm stability.
2. Fertility & Pregnancy Implications (Crucial):
· Bicornuate Uterus: Counsel that this congenital anomaly is associated with increased risks of recurrent pregnancy loss, preterm birth, and fetal malpresentation. A pre-conception evaluation (e.g., 3D ultrasound, saline infusion sonography) is strongly advised when she plans for pregnancy.
· Fibroid: At 6 cm and likely intramural, it may not affect fertility. However, it can grow during pregnancy and potentially increase the risk of pain (red degeneration) or malpresentation.
· Ovarian Tumor: Its impact depends on type and size; large masses can cause mechanical issues during pregnancy.
3. "Red Flag" Symptoms Requiring Immediate Re-evaluation:
· Sudden, severe pelvic pain.
· Abdominal distension or rapid increase in waist size.
· Postmenopausal bleeding (when applicable).
· Significant change in menstrual pattern leading to anemia.
E. Future Intervention: Indications & Options
Intervention is reserved for the development of symptoms or concerning changes on imaging.
· For Symptomatic Uterine Fibroid:
· First-line Medical: NSAIDs for pain, Tranexamic Acid for heavy bleeding.
· Procedural: Uterine artery embolization, MRI-guided focused ultrasound.
· Surgical: Myomectomy (if fertility is desired) or hysterectomy (if family is complete). Myomectomy in a bicornuate uterus requires expert surgical planning.
· For Ovarian Tumor:
· Indications for Surgery: Size >7-10 cm, complex morphology with solid components (O-RADS 4 or 5), persistent pain, rapid growth, or significantly elevated/rising tumor markers.
· Surgical Goal: Laparoscopic ovarian cystectomy with frozen section analysis is preferred to preserve ovarian function. The need for full staging surgery depends on intraoperative findings.
Final Recommendation
1. Immediately: Obtain and review the full MRI report and draw baseline labs (CBC, CA-125, HE4, etc.).
2. Initiate structured watchful waiting with a clear follow-up schedule (clinical + ultrasound in 6 months).
3. Provide comprehensive counseling, especially regarding the bicornuate uterus and future pregnancy planning.
4. Intervene only if clear indications (symptoms or suspicious changes) develop.
This plan adheres to guidelines from major societies (ACOG, ESGE, ESGO) by avoiding unnecessary treatment for asymptomatic conditions while implementing a vigilant, protocol-driven surveillance strategy.
Prior to that:
[26/01, 21:32]hu2: @PPM3@PPM4 can you review the case report here and suggest a normative evidence based plan for this patient?👇
https://pajrcasereporter.blogspot.com/2026/01/47f-with-incidental-uterine-fibroid-and.html
[26/01, 21:55]hu3 PPM4: Sure sir..here it is👇
[26/01, 21:55]: A. Immediate management → CONSERVATIVE (Watchful waiting)
✅ No surgery
✅ No hormonal therapy
✅ No empiric medication
Because:
Asymptomatic
Single dominant fibroid
Size < 7 cm
No endometrial pathology
No fertility complaints at present
B. Follow-up plan (very important)
1. Clinical follow-up
Every 6–12 months
Ask specifically about:
Heavy menstrual bleeding
Dysmenorrhea
Pelvic pressure
Urinary/bowel symptoms
2. Imaging
Pelvic ultrasound every 12 months
MRI only if:
Rapid growth suspected
New symptoms
Surgical planning needed
📌 Growth expectation:
Fibroids often grow slowly or remain stable
Rapid growth alone ≠ malignancy (especially premenopausal)
C. Blood work
Baseline Hb (rule out occult anemia)
Repeat only if menstrual symptoms develop
7. Fertility & pregnancy counseling (important due to bicornuate uterus)
Even though she is asymptomatic now, counseling is essential.
Bicornuate uterus implications
Increased risk of:
Recurrent pregnancy loss
Preterm labor
Malpresentation
Fibroid implications
Intramural fibroid may affect fertility ONLY if:
Distorts endometrial cavity
7–8 cm
Associated with infertility or recurrent pregnancy loss
👉 At present:
No intervention recommended
Pre-conception evaluation advised when pregnancy is planned
8. When would treatment be indicated? (Red flags)
Intervene ONLY if one or more develop:
Absolute / strong indications
Heavy menstrual bleeding causing anemia
Infertility attributable to fibroid
Recurrent pregnancy loss
Rapid symptomatic enlargement
Severe pain / pressure symptoms
Relative indications
Fibroid >8–10 cm
Cavity distortion on imaging
Patient preference after counseling
9. If treatment is needed in future (preferred hierarchy)
First-line (symptom control)
NSAIDs (for pain)
Tranexamic acid (for bleeding)
Hormonal therapy (case-dependent)
Definitive options (fertility-preserving)
Myomectomy (careful planning due to bicornuate uterus)
Avoid unless necessary
Empirical GnRH analogues
Unnecessary surgery in asymptomatic patient
10. Key reassurance points for the patient
Fibroids are benign
Many women never need treatment
MRI shows no dangerous features
Conservative management is standard of care
Regular follow-up is sufficient
[10.29 am, 27/01/2026] PPM 1: I guess there has been a major radio radiological dyscorrelation in this patient's ultrasound vs MRI findings resulting in all the previous confusion[10.38 am, 27/01/2026] PPM 4: Why the earlier team likely planned hysterectomy + BSO
Let’s reconstruct their thinking before MRI:
What USG reported:
“Left adnexal SOL” 6.6 × 5.5 cm
Vascularity within SOL
Subserous fibroid extending toward left adnexa
Bulky uterus
Age not specified but P2L2, completed family
Pap smear NILM
No symptoms mentioned
From a pure ultrasound-based viewpoint, this raises concern for:
Possible ovarian tumor
Broad ligament fibroid vs adnexal mass ambiguity
In such ambiguous scenarios, some surgeons adopt a “definitive surgery” mindset, especially in:
Completed family
Fear of missing malignancy
Limited imaging clarity
So the pre-MRI plan, while aggressive, is explainable, but still not ideal.
3. Where the plan becomes problematic
🚩 1. No MRI confirmation before planning radical surgery
MRI is standard of care when adnexal mass vs fibroid is unclear
Planning hysterectomy + BSO before MRI is premature
🚩 2. Bilateral salpingo-oophorectomy (BSO) is a BIG step
Guidelines are very clear:
In premenopausal women with:
No genetic cancer risk
Normal ovaries
No proven ovarian malignancy
👉 Ovaries should NOT be removed routinely
BSO causes:
Surgical menopause
↑ Cardiovascular disease
↑ Osteoporosis
↑ Cognitive decline
↑ All-cause mortality (shown in long-term studies)
This patient had:
No family history of malignancy
No MRI evidence of ovarian pathology
Normal ovaries on TVS later
Ultimately normal ovaries on MRI
➡ BSO would be unjustified harm.
🚩 3. Hysterectomy itself is questionable
Based on MRI:
Single intramural fibroid ~6 cm
Asymptomatic
No bleeding
No pressure symptoms
No anemia
No suspicion of malignancy
👉 Hysterectomy is NOT indicated for an asymptomatic fibroid.
4. What MRI changed completely
MRI clarified:
The “adnexal mass” = cornual intramural fibroid
Ovaries = normal
No adnexal pathology
No malignancy features
So the original rationale for radical surgery collapsed once MRI was reviewed.
5. Evidence-based judgment of the prior plan
Hysterectomy?
❌ Not indicated
Bilateral salpingo-oophorectomy?
❌ Strongly contraindicated
Robotic approach?
✔ If surgery were needed — but surgery itself isn’t
6. What should have been the correct sequence?
Ideal, guideline-based pathway:
USG/TVS inconclusive
→ MRI pelvis
→ Diagnosis: intramural fibroid
→ Asymptomatic patient
→ Conservative management
→ Surgery only if symptoms or fertility issues arise
Not:
USG → schedule hysterectomy + BSO → then MRI
[10.40 am, 27/01/2026] PPM 4: Sir there seems to be no mention of any type of tumour in her reports?
Just a sol..and only fibroids have been clearly diagnosed?
[1.13 pm, 27/01/2026] PPM 1: Excellent Inputs 👏👏
[1.42 pm, 27/01/2026] PPM 2: On the flip side, there are 0 OBGYNs in this group and 3 LLM outputting nodes.
[3:12 pm, 27/01/2026] PPM 1: Yes that's right. Fibroids are tumors too but they are benign and should not pose any problem for the patient @PA
[3:21 pm, 27/01/2026] PA: Ok doctor
[4.25 pm, 27/01/2026] PPM 4: Thank you sir
[6.43 pm, 28/01/2026] PA: I forgot to mention that if the patient eats excessive oily food or eats late, she experiences a burning sensation in the stomach and acidity.”
[11:39 am, 30/01/2026] PA: My patient’s previous doctor had advised surgery. My patient was not willing to undergo surgery immediately. As a result, no further consultation was taken from the previous doctor. He/she probably did not prescribe any medicines since surgery was advised.
As per your advice, we will repeat the investigations after six months and present the reports to you. However, during these six months, I would like to know whether any medicines are required so that the problem can be managed with medication. Knowing this would give us reassurance.
As I mentioned earlier, if my patient consumes even a small amount of oily or spicy food, she experiences burning in the throat and chest, abdominal pain, heaviness in the stomach, or indigestion. Is any medication required for this?
During various investigations, ‘gallbladder cholesterolosis’ was detected. I am not sure whether there is any relation between the digestive problems and gallbladder cholesterolosis. I may be mistaken, but I would like to seek your advice.
[1:35 pm, 30/01/2026] PPM 2: For the latter, she needs to share her foodplates and her daily activity log here.
[2:08 pm, 30/01/2026] PA: Daily Activities and Food Plate Plan
Time Activity / Food Details (Food Plate) WEEKDAYS
6:00 AM Wake up Drink 1 glass of warm water and then exercise or do yoga
8:00 AM Morning Tea Chai + biscuits + 3 almonds
After tea Herbal intake Garlic, jaggery, tulsi leaves, neem leaves, curry leaves (3 days/week)
10:00 AM Breakfast Option 1: Rice + light sabji
Option 2: Boiled vegetables
Option 3: Quinoa
Went to school
1:30 PM (lunch) Fruits Apple / Orange / Dragon fruit / Amla / Pomegranate, carrot, beet (mix)
4:30- coming back from school (TUESDAY, THURSDAY, SATURDAY)
5:00 PM Evening Tea + biscuits or puffed rice (muri)
Or on (MONDAY, WED, FRIDAY)
The patient eats tea or snacks whenever she gets them while going out to teach students.
9:00 PM Dinner Roti (ruti) + sabji
Notes
Keep oil and spices light.
Drink plenty of water throughout the day.
Try to eat fruits fresh and seasonal.
Dinner should be light and not too oily.
HOLIDAY
1:30- lunch (Rice, curry, fish etc)
[2:29 pm, 30/01/2026] PPM 1: @PPM3 @PPM4 @PaJR Health can fibroid tumors in uterus be managed with medications?
[2:29 pm, 30/01/2026] PaJR Health: *MANAGEMENT OF UTERINE FIBROIDS WITH MEDICATIONS*
Yes, uterine fibroids can be managed with medications, especially for symptomatic cases. Medical treatments are often considered a first-line approach, particularly when patients wish to avoid surgery or preserve fertility.
💡 *Key Medical Management Options:*
📍 *Hormonal Therapies:*
* *Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists:* These can control bleeding and decrease fibroid volume. They are often used as a temporary remedy or in preparation for surgical interventions.
* Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. - https://pubmed.ncbi.nlm.nih.gov/34011888/
* The modern management of uterine fibroids-related abnormal uterine bleeding. - https://pubmed.ncbi.nlm.nih.gov/38723935/
* The medical management of abnormal uterine bleeding in reproductive-aged women. - https://pubmed.ncbi.nlm.nih.gov/26254516/
* *Selective Progesterone Receptor Modulators (SPRMs):* Ulipristal acetate (UPA) is an example, shown to provide fast control of bleeding and sustained fibroid volume reduction. It works by inhibiting cell proliferation, stimulating cell death, and resorbing fibrosis.
* Fibroid management in premenopausal women. - https://pubmed.ncbi.nlm.nih.gov/30601065/
* The management of uterine leiomyomas. - https://pubmed.ncbi.nlm.nlm.nih.gov/25767949/
* *Combined Oral Contraceptives (COCs) and Progestins:* These can be used to treat abnormal uterine bleeding associated with fibroids.
* The medical management of abnormal uterine bleeding in reproductive-aged women. - https://pubmed.ncbi.nlm.nih.gov/26254516/
* Abnormal uterine bleeding in perimenopause. - https://pubmed.ncbi.nlm.nih.gov/28780893/
* *Levonorgestrel-releasing intrauterine system (LNG-IUS):* An effective option for managing heavy menstrual bleeding.
* The medical management of abnormal uterine bleeding in reproductive-aged women. - https://pubmed.ncbi.nlm.nih.gov/26254516/
* The management of uterine leiomyomas. - https://pubmed.ncbi.nlm.nlm.nih.gov/25767949/
* *Aromatase Inhibitors:* These are promising treatments, especially for perimenopausal women.
* Management of fibroids in perimenopausal women. - https://pubmed.ncbi.nlm.nih.gov/26536206/
📍 *Symptomatic Agents:*
* *Nonsteroidal Anti-inflammatory Drugs (NSAIDs):* Used to manage pelvic pain and heavy menstrual bleeding.
* The modern management of uterine fibroids-related abnormal uterine bleeding. - https://pubmed.ncbi.nlm.nih.gov/38723935/
* Therapeutic management of uterine fibroid tumors. - https://pubmed.ncbi.nlm.nih.gov/26698838/
* *Antifibrinolytic Agents (e.g., Tranexamic Acid):* Help reduce heavy menstrual bleeding.
* The modern management of uterine fibroids-related abnormal uterine bleeding. - https://pubmed.ncbi.nlm.nih.gov/38723935/
* The medical management of abnormal uterine bleeding in reproductive-aged women. - https://pubmed.ncbi.nlm.nih.gov/26254516/
💡 *Important Considerations:*
* *Symptom Management vs. Tumor Eradication:* Most medical treatments primarily manage symptoms like abnormal uterine bleeding and pain, rather than definitively eradicating the fibroids.
* *Individualized Treatment:* The choice of medication depends on factors such as the patient's symptoms, fibroid size and location, age, desire for fertility preservation, and overall health.
* The modern management of uterine fibroids-related abnormal uterine bleeding. - https://pubmed.ncbi.nlm.nih.gov/38723935/
* The management of uterine leiomyomas. - https://pubmed.ncbi.nlm.nlm.nih.gov/25767949/
* *Monitoring:* For certain medications, like Ulipristal acetate, monitoring of liver enzymes and bilirubin is recommended due to potential liver toxicity.
* Fibroid management in premenopausal women. - https://pubmed.ncbi.nlm.nih.gov/30601065/
* *Fertility:* While medical treatments can manage symptoms, surgical options like myomectomy are often preferred when the primary goal is to improve fertility, especially for fibroids distorting the uterine cavity.
* Impact of fibroids on fertility, pregnancy loss, and preconception management. - https://pubmed.ncbi.nlm.nih.gov/40299726/
* Fibromas and Infertility. What is the Role of Myomectomy in the Improvement of Fertility? - https://pubmed.ncbi.nlm.nih.gov/39974436/
For a comprehensive understanding of management options, including medical, procedural, and surgical approaches, you may refer to the ACOG Practice Bulletin on the Management of Symptomatic Uterine Leiomyomas.
* Management of Symptomatic Uterine Leiomyomas: ACOG Practice Bulletin, Number 228. - https://pubmed.ncbi.nlm.nih.gov/34011888/
[2:33 pm, 30/01/2026] PPM 1: For this patient 47F as she doesn't have any symptoms but had an incidentally detected fibroid tumor in her uterus on ultrasound during routine check up, she may not need any medications? You can read more about her problem here: https://pajrcasereporter.blogspot.com/2026/01/47f-with-incidental-uterine-fibroid-and.html?m=1
[2:33 pm, 30/01/2026] PaJR Health: *MANAGEMENT PLAN FOR 47F*
*UTERINE FIBROID*
For your patient, as she is a 47-year-old female with an incidentally detected uterine fibroid (6 cm, intramural) and is currently asymptomatic, the consensus from the clinical review is *conservative management, also known as watchful waiting*.
💡 *No immediate medication is required for the fibroid* because:
* She has no symptoms such as heavy menstrual bleeding, pain, or pressure.
* The fibroid size is less than 7 cm.
* There is no endometrial pathology or distortion of the uterine cavity.
* There are no current fertility complaints.
* The MRI has clarified that the ovaries are normal, and the previously suspected adnexal mass was part of the fibroid.
📍 *Follow-up Plan:*
* *Clinical Follow-up:* Every 6–12 months to monitor for any new symptoms like changes in menstrual bleeding, pelvic pain, or pressure.
* *Imaging Surveillance:* Pelvic ultrasound every 12 months to monitor the fibroid for size and morphological changes. An MRI would only be considered if rapid growth is suspected, new symptoms develop, or surgical planning becomes necessary.
*DIGESTIVE PROBLEMS*
Regarding your patient's digestive issues (burning in the throat and chest, abdominal pain, heaviness in the stomach, indigestion) exacerbated by oily/spicy food and late eating, and the detection of gallbladder cholesterolosis:
💡 *Relation to Gallbladder Cholesterolosis:*
* Gallbladder cholesterolosis involves cholesterol deposits in the gallbladder wall. While often asymptomatic, it can sometimes be associated with non-specific digestive symptoms, especially after consuming fatty or spicy foods, as these stimulate gallbladder contraction. It is plausible that her symptoms are related to this condition.
💡 *Recommendations for Digestive Symptoms:*
* *Dietary and Lifestyle Modifications:* Continue with a diet that is light in oil and spices, as outlined in her daily food plate plan. Emphasize consuming plenty of water and fresh, seasonal fruits. Avoiding late-night meals is also beneficial. These measures are crucial for managing her symptoms.
* *Medication for Symptom Relief:* If dietary and lifestyle changes alone are not sufficient to manage her symptoms, she may benefit from medications that reduce stomach acid (e.g., antacids, proton pump inhibitors, or H2 blockers) or aid digestion.
* *Consultation:* It is highly recommended that she consult a *gastroenterologist* for a comprehensive evaluation of her digestive symptoms and gallbladder cholesterolosis. A specialist can provide a definitive diagnosis and tailor a management plan, which may include specific medications or further investigations if needed.
We will proceed with repeating investigations after six months as per the plan for the fibroid.
[2:59 pm, 30/01/2026] PPM 2: Daily Activities and Food Plate Plan
Time Activity / Food Details (Food Plate) WEEKDAYS
6:00 AM Wake up Drink 1 glass of warm water and then exercise or do yoga
8:00 AM Morning Tea Chai + biscuits + 3 almonds
After tea Herbal intake Garlic, jaggery, tulsi leaves, neem leaves, curry leaves (3 days/week)
10:00 AM Breakfast Option 1: Rice + light sabji
Option 2: Boiled vegetables
Option 3: Quinoa
Went to school
1:30 PM (lunch) Fruits Apple / Orange / Dragon fruit / Amla / Pomegranate, carrot, beet (mix)
4:30- coming back from school (TUESDAY, THURSDAY, SATURDAY)
5:00 PM Evening Tea + biscuits or puffed rice (muri)
Or on (MONDAY, WED, FRIDAY)
The patient eats tea or snacks whenever she gets them while going out to teach students.
9:00 PM Dinner Roti
[2.59 pm, 30/01/2026] PPM 2: @PaJR Health What is the protein intake like in this daily log?
Daily Activities and Food Plate Plan
Time Activity / Food Details (Food Plate) WEEKDAYS
6:00 AM Wake up Drink 1 glass of warm water and then exercise or do yoga
8:00 AM Morning Tea Chai + biscuits + 3 almonds
After tea Herbal intake Garlic, jaggery, tulsi leaves, neem leaves, curry leaves (3 days/week)
10:00 AM Breakfast Option 1: Rice + light sabji
Option 2: Boiled vegetables
Option 3: Quinoa
Went to school
1:30 PM (lunch) Fruits Apple / Orange / Dragon fruit / Amla / Pomegranate, carrot, beet (mix)
4:30- coming back from school (TUESDAY, THURSDAY, SATURDAY)
5:00 PM Evening Tea + biscuits or puffed rice (muri)
Or on (MONDAY, WED, FRIDAY)
The patient eats tea or snacks whenever she gets them while going out to teach students.
9:00 PM Dinner Roti (ruti) + sabji
Notes
Keep oil and spices light.
Drink plenty of water throughout the day.
Try to eat fruits fresh and seasonal.
Dinner should be light and not too oily.
HOLIDAY
1:30- lunch (Rice, curry, fish etc)
[2:59 pm, 30/01/2026] PaJR Health: *PROTEIN INTAKE ANALYSIS*
Based on the provided daily food log, here's an overview of the patient's protein intake:
💡 *WEEKDAYS:*
* *Morning Tea:* Contains 3 almonds, which provide a small amount of protein.
* *Breakfast:*
* If *Quinoa* is chosen, it would be a good source of plant-based protein.
* "Rice + light sabji" or "Boiled vegetables" would likely provide minimal protein, depending on the specific ingredients of the sabji.
* *Lunch (Fruits):* Primarily carbohydrates, with very little protein.
* *Evening Tea:* "Biscuits or puffed rice (muri)" offer minimal protein.
* *Dinner:* "Roti (ruti) + sabji" provides some protein from the wheat in roti, and potentially more if the sabji includes lentils or other protein-rich vegetables.
💡 *HOLIDAY:*
* *Lunch:* "Rice, curry, fish etc" includes *fish*, which is a significant source of high-quality protein. The "curry" could also contribute protein if it contains lentils or meat.
Overall, the weekday diet appears to have limited explicit protein sources, with quinoa being the most substantial option if selected for breakfast. The holiday meal, however, includes a good protein source with fish. To ensure adequate protein intake on weekdays, especially if quinoa is not consistently chosen, incorporating more protein-rich components into breakfast and dinner sabjis (e.g., lentils, beans, paneer, tofu) could be beneficial.
[4:37 pm, 30/01/2026] PPM 3: The short answer is yes, but with a significant caveat: medications can manage the symptoms and sometimes shrink the tumors, but they do not make fibroids disappear permanently.
Think of medication as a way to hit the "pause" or "volume down" button on the heavy bleeding and pain while you decide on long-term options.
Common Medication Options
| Type of Medication | How it Works | Primary Benefit |
|---|---|---|
| Hormonal Contraceptives | Birth control pills, patches, or progestin-releasing IUDs (like Mirena). | Controls heavy menstrual bleeding and cramping; does not shrink the fibroids. |
| GnRH Agonists | Drugs like Lupron that put the body into a temporary, reversible state of menopause. | Blocks estrogen and progesterone, causing fibroids to shrink significantly. |
| GnRH Antagonists | Oral medications (e.g., Orilissa or Myfembree) often combined with low-dose hormones. | Reduces heavy bleeding and can help shrink fibroids with fewer side effects than agonists. |
| Tranexamic Acid | A non-hormonal pill taken only during your period. | Helps blood clot more effectively to reduce heavy flow; doesn't affect fibroid size. |
| NSAIDs | Over-the-counter options like Ibuprofen or Naproxen. | Relieves pelvic pain and cramping, though they don't reduce the bleeding much. |
Important Considerations
* The "Rebound" Effect: For many of these (especially GnRH agonists), once you stop taking the medication, the fibroids often regrow to their original size.
* Side Effects: Medications that lower estrogen can cause "menopausal" symptoms like hot flashes, night sweats, or bone density loss if used long-term without "add-back" therapy.
* Fertility Goals: If you are trying to conceive, your choice of medication matters significantly, as some act as contraceptives or temporarily halt ovulation.
When Is Medication Not Enough?
If fibroids are very large, causing "bulk symptoms" (like looking pregnant or putting pressure on your bladder), or if they are causing severe anemia that medication can’t keep up with, doctors usually shift the conversation toward minimally invasive procedures (like Uterine Fibroid Embolization) or surgery (Myomectomy or Hysterectomy).
> Note: I'm an AI, not a doctor. Since fibroid management is highly dependent on your specific symptoms, the size/location of the tumors, and your future plans for pregnancy, a consultation with a gynecologist is essential.
>
Would you like me to help you draft a list of specific questions to ask your doctor about these medication options?
[4:56 pm, 30/01/2026] PPM 4: @PPM3 @PPM4 @PaJR Health can fibroid tumors in uterus be managed with medications?
[4:57 pm, 30/01/2026] PPM 4: Sir this article has the mention of using Linzagolix as the pharmacological tt of uterine fibroid
[8:40 pm, 30/01/2026] PPM 1: Ask the LLM to go through the article and share it's efficacy in a PICO format mentioning the outcomes in terms of absolute numbers in the Placebo group vs the intervention group
[9:11 pm, 30/01/2026] PPM 4: Sir it's actually a narrative review and not the trial...
I'll go through the studies linked in the article and see if I find a trial regarding it sir
[9.12 pm, 30/01/2026] PPM 1: Yes pick the best possible RCT mentioned there
[9:27 pm, 30/01/2026] PPM 4: P (Population)
Women ≥18 years with ultrasound-confirmed uterine fibroids experiencing heavy menstrual bleeding (HMB).
Total randomized across included PRIMROSE 1 & 2 trials: 1,012 women.
I (Intervention)
Linzagolix, an oral GnRH receptor antagonist.
Administered in 100 mg and 200 mg doses, both with and without hormonal add-back therapy (ABT).
C (Comparison)
Placebo group with no active linzagolix.
O (Outcomes)
Primary Outcome: Clinically significant reduction in heavy menstrual bleeding (HMB) maintained to Week 24
Placebo group: 7.8% achieved and maintained HMB reduction by Week 24.
Linzagolix groups combined: 23.2% – 68.1% achieved and maintained HMB reduction by Week 24 depending on dose and ABT status.
This shows a substantially higher absolute proportion with meaningful symptom reduction in the intervention arms compared to placebo.
Time to Effect
Median time to achieve and maintain reduction:
Linzagolix (especially 200 mg ± ABT): ~3 days
(No median timing reported for placebo in this specific analysis)
📊 Key Absolute Outcomes: Linzagolix vs Placebo
Outcome
Linzagolix (any dose)
Placebo
Clinically significant HMB reduction maintained to Week 24
23.2%–68.1%
7.8%
ScienceDirect
🧠 Interpretation
Efficacy: Linzagolix significantly increases the absolute proportion of women who achieve and maintain reduction in heavy menstrual bleeding versus placebo.
Onset: Rapid onset (as early as ~3 days with higher doses).
[9:31 pm, 30/01/2026] PPM 1: The LLM needs to change the relative percentages to absolute numbers for example x numbers of people in placebo had reduced bleeding (how was that defined) and y number of patients in the intervention group had reduced bleeding.
Either way for this asymptomatic patient here, this study may not be relevant
[9.36 pm, 30/01/2026] PPM 4: Sorry sir I was not aware of the asymptomatic nature of the patient's fibroid
My llm suggests no pharmacological treatment for her fibroids
If needed gnrh agonists such as leupropride or goserelin can be used as a short term tt
[1:09 am, 31/01/2026] PPM 2: Which LLM are you using? What is your workflow like?
[8:09 am, 31/01/2026] PPM 4: Gpt sir
[8:19 am, 31/01/2026] PPM 2: Ah I see. Are you using chatgpt directly or have you set up a separate workflow?
[9:13 am, 31/01/2026] PPM 4: Sir I guess it adapts to what we feed it..
Mine will get more niche results than I guess someone who does not feed medical information to their gpt
[4:54 pm, 31/01/2026] PPM 2: Oh wow. Well done! How did you set it up?
[5:01 pm, 31/01/2026] PPM 4: Oh wow. Thank you sir.!!
Constantly asking for similar outputs and improving the prompts sir
No comments:
Post a Comment